Nivolumab + Ipilimumab for Pituitary Cancer

Recruiting in Palo Alto (17 mi)

+11 other locations

Overseen byAndrew Lin, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Eligibility Criteria

Adults with aggressive pituitary tumors that have worsened after surgery and radiation can join this trial. They must not need high doses of steroids, have no severe autoimmune diseases or infections like HIV/HBV/HCV, and women must avoid pregnancy.

Inclusion Criteria

Women of childbearing potential must have a negative pregnancy test when they join the study.

I have a tumor in my pituitary gland.

Your blood test results must meet certain standards.

+9 more

Exclusion Criteria

Patients should be excluded if they have a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

History of allergy to study drug components

You have had a strong allergic reaction to any monoclonal antibody in the past.

+6 more

Participant Groups

The study is testing the effectiveness of two drugs, Nivolumab and Ipilimumab, in treating pituitary tumors that are unresponsive to traditional treatments like surgery and radiation.

1Treatment groups

Experimental Treatment

Group I: Pituitary CancerExperimental Treatment2 Interventions

Participants will have a pituitary adenoma/carcinoma of any histology